drugset / Trial / NCT00169533
Rollover Study Of Lapatinib In Cancer Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The EGF19060 study is a rollover study to evaluate the long term safety of lapatinib and to provide lapatinib to patients who had a positive response in previous lapatinib studies until lapatinib is available pending FDA approval.
Timeline
- Start
- 2004-08-19
- Primary completion
- 2009-05-05
- Completion
- 2009-05-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lapatinib | Small molecule | 750 mg | Oral |
| Subject | Lapatinib | Small molecule | 1000 mg | Oral |
| Subject | Lapatinib | Small molecule | 1250 mg | Oral |
| Subject | Lapatinib | Small molecule | 1500 mg | Oral |